浙江医学2011，Vol.33Issue(1)：18-20,3.
早期单剂多药联合膀胱序贯疗法预防浅表性膀胱癌术后复发疗效分析
Postoperative prophylaxis of recurrence of superficial bladder cancer by single dose intravesical instillations with multi-drugs: a prospective randomized controlled study
摘要
Abstract
Objective To compare the efficacy and safety of single dose intravesical instillation of multi-drugs with multiple instillations of pirarubicin or mitomycin C for postoperative prophylaxis of superficial bladder cancer. Methods Ninty two patients with superficial bladder cancer were assigned to three arms: 31 patients received a single dose sequential intravesical instillation of 30 mg pirarubicin, 20mg hydroxycamptothecin, 10mg BCG polysaccharide, 30mg mitomycin and interferon α-2b 5,000,000 u within 24 h after operation (combination group); 32 patients received intravesical instillation of 20mg pirarubicin (pirarubicin group) and 29 patients instillation of 20mg mitomycin (mitomycin group), for last two groups the intravesical instillations were repeated for 6 weeks and thereafter monthly for 1 year. Results The recurrence rates for 3 groups were 16.1％ (5/31), 12.5 ％(4/32) and 17.2％ (5/29), respectively (P ＞0.05). Kaplan -Meier analysis of disease free interval for the 3 groups showed no significant difference (P ＞0.05). The rate of adverse effects in combination group was lower than that of other two groups (P＜0.05).Conclusion For well differentiated, early stage superficial bladder cancer single dose intravesical instillation of multi-drugs is effective in prophylaxis of recurrence with advantage of cost-effective and less adverse effects.关键词
膀胱肿瘤/化学免疫治疗/序贯疗法/复发引用本文复制引用
缪江伟,张斌斌,李奇孟,黄翔,方伟杰..早期单剂多药联合膀胱序贯疗法预防浅表性膀胱癌术后复发疗效分析[J].浙江医学,2011,33(1):18-20,3.基金项目
温州市社会发展科学研究项目(Y20090072) （Y20090072）
